BioNTech's BNT113 Misses Its First Hurdle, Putting Survival Data in the Spotlight

BioNTech shares ended Friday at €78.05, down 3.0%, as investors digested a clinical setback in the Mainz-based company's oncology pipeline. The close leaves the stock 26% below its 52-week high of €105.80, with the 52-week low of €68.35 now standing as the technical line in the sand.

At the heart of the pullback is the Phase 2/3 AHEAD-MERIT trial, which pairs the company's mRNA cancer immunotherapy candidate BNT113 with the checkpoint inhibitor pembrolizumab against pembrolizumab alone in patients with metastatic, HPV16-positive head and neck cancer. The first analysis showed no statistically significant improvement in progression-free survival for the combination over the checkpoint inhibitor on its own — the study's first dual primary endpoint. BioNTech disclosed the update in a mandatory Form 6-K filing with the US Securities and Exchange Commission.

The Trial Is Down, Not Out

The program has not been scrapped. AHEAD-MERIT continues as planned, with attention now fixed on the second dual primary endpoint: overall survival. In oncology, that metric carries the greatest medical and commercial weight, and it will decide whether BNT113 has a future in this indication. A statistically meaningful survival benefit versus standard therapy would keep the door open to a later marketing approval; a second miss would threaten the program's prospects in the studied setting.

That the trial was allowed to run rather than halted early gives the more optimistic camp an argument. Cancer immunotherapy has produced cases where clinical benefit only emerges in overall survival data, and hopeful investors read the continuation as a sign that BNT113's therapeutic potential should not be written off prematurely. The bull case also leans on the breadth of BioNTech's pipeline, which they see as capable of absorbing isolated setbacks — and they regard the recent share-price weakness as an overreaction. The stakes are high because the market, with the Covid-19 vaccine business in decline, is counting on landmark clinical wins in cancer therapy; late-stage disappointments hit confidence in the pipeline fast.

Canaccord Trims Its Model but Stays Bullish

Canaccord Genuity offered some support for that view on Wednesday. Analyst William Maughan cut his price target to $132 from $136 while keeping a Buy rating, explicitly citing the missed statistical goal on progression-free survival in the BNT113 program as the reason for the model adjustment.

Skeptics have a concrete counterargument. Missing the first primary endpoint in a late-stage Phase 2/3 study is a serious blow, and experience suggests the odds of demonstrating a convincing overall survival advantage drop after a progression-free survival failure. Should BNT113 also fall short on overall survival, the company would have to book a painful setback for this cancer program. With expectations for the oncology pipeline running high, every disappointment in an advanced program raises the pressure on management to steer other projects toward approval.

Insider Sales Draw a Glance

Beyond the trial news, market participants also noted transactions from the top floor. CEO U?ur ?ahin sold shares in early October under a pre-arranged Rule 10b5-1 trading plan set up on June 3, 2026. He offloaded 72,000 ordinary shares on October 5, followed by 21,000 on October 6 and a further 24,000 ordinary shares on October 7. Because such sales are scheduled months in advance through automated plans, they generally do not reflect short-term operational developments — though they attract attention when they land amid clinical setbacks.

The next concrete catalyst is the further readout from AHEAD-MERIT. Once the overall survival data arrive, the path forward for BNT113 will be settled. Until then, the stock is likely to stay hostage to news on the clinical front, with the €68.35 floor marking the level that would darken the chart picture materially if it were to give way.